243 related articles for article (PubMed ID: 28253830)
1. Advances in emerging drugs for the treatment of neuroblastoma.
Berlanga P; Cañete A; Castel V
Expert Opin Emerg Drugs; 2017 Mar; 22(1):63-75. PubMed ID: 28253830
[TBL] [Abstract][Full Text] [Related]
2. Emerging drugs for neuroblastoma.
Castel V; Segura V; Berlanga P
Expert Opin Emerg Drugs; 2013 Jun; 18(2):155-71. PubMed ID: 23692586
[TBL] [Abstract][Full Text] [Related]
3. Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.
Amoroso L; Haupt R; Garaventa A; Ponzoni M
Expert Opin Investig Drugs; 2017 Nov; 26(11):1281-1293. PubMed ID: 28906153
[TBL] [Abstract][Full Text] [Related]
4. Advances in pharmacotherapy for neuroblastoma.
Pezeshki PS; Moeinafshar A; Ghaemdoust F; Razi S; Keshavarz-Fathi M; Rezaei N
Expert Opin Pharmacother; 2021 Dec; 22(17):2383-2404. PubMed ID: 34254549
[TBL] [Abstract][Full Text] [Related]
5. Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project.
Moreno L; Caron H; Geoerger B; Eggert A; Schleiermacher G; Brock P; Valteau-Couanet D; Chesler L; Schulte JH; De Preter K; Molenaar J; Schramm A; Eilers M; Van Maerken T; Johnsen JI; Garrett M; George SL; Tweddle DA; Kogner P; Berthold F; Koster J; Barone G; Tucker ER; Marshall L; Herold R; Sterba J; Norga K; Vassal G; Pearson AD
Expert Opin Drug Discov; 2017 Aug; 12(8):801-811. PubMed ID: 28604107
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms and therapeutic targets in neuroblastoma.
Johnsen JI; Dyberg C; Fransson S; Wickström M
Pharmacol Res; 2018 May; 131():164-176. PubMed ID: 29466695
[TBL] [Abstract][Full Text] [Related]
7. Pharmacotherapy of neuroblastoma.
George RE; Diller L; Bernstein ML
Expert Opin Pharmacother; 2010 Jun; 11(9):1467-78. PubMed ID: 20408767
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic strategies for the treatment of neuroblastoma.
Izbicka E; Izbicki T
Curr Opin Investig Drugs; 2005 Dec; 6(12):1200-14. PubMed ID: 16370386
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Innovations for Targeting Childhood Neuroblastoma: Implications of the Neurokinin-1 Receptor System.
Berger M; VON Schweinitz D
Anticancer Res; 2017 Nov; 37(11):5911-5918. PubMed ID: 29061769
[TBL] [Abstract][Full Text] [Related]
10. Emerging therapeutic targets for neuroblastoma.
Aravindan N; Herman T; Aravindan S
Expert Opin Ther Targets; 2020 Sep; 24(9):899-914. PubMed ID: 33021426
[TBL] [Abstract][Full Text] [Related]
11. Safety of mTOR inhibitors in breast cancer.
Študentová H; Vitásková D; Melichar B
Expert Opin Drug Saf; 2016 Aug; 15(8):1075-85. PubMed ID: 27210004
[TBL] [Abstract][Full Text] [Related]
12. Emerging treatment for ALK-positive lung cancer.
Sharma J; Pareek V; Liu H; Cheng H
Expert Opin Emerg Drugs; 2016 Jun; 21(2):147-55. PubMed ID: 27122312
[TBL] [Abstract][Full Text] [Related]
13. Additional Therapies to Improve Metastatic Response to Induction Therapy in Children With High-risk Neuroblastoma.
Schrey D; Vaidya SJ; Levine D; Pearson AD; Moreno L
J Pediatr Hematol Oncol; 2015 Apr; 37(3):e150-3. PubMed ID: 26201036
[TBL] [Abstract][Full Text] [Related]
14. Overview and recent advances in the treatment of neuroblastoma.
Whittle SB; Smith V; Doherty E; Zhao S; McCarty S; Zage PE
Expert Rev Anticancer Ther; 2017 Apr; 17(4):369-386. PubMed ID: 28142287
[TBL] [Abstract][Full Text] [Related]
15. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
16. Methodological advances in the discovery of novel neuroblastoma therapeutics.
Segura MF; Soriano A; Roma J; Piskareva O; Jiménez C; Boloix A; Fletcher JI; Haber M; Gray JC; Cerdá-Alberich L; Martínez de Las Heras B; Cañete A; Gallego S; Moreno L
Expert Opin Drug Discov; 2022 Feb; 17(2):167-179. PubMed ID: 34807782
[TBL] [Abstract][Full Text] [Related]
17. Targeted Therapy for Neuroblastoma: ALK Inhibitors.
Schulte JH; Schulte S; Heukamp LC; Astrahantseff K; Stephan H; Fischer M; Schramm A; Eggert A
Klin Padiatr; 2013 Nov; 225(6):303-8. PubMed ID: 24166094
[TBL] [Abstract][Full Text] [Related]
18. Development of differentiation modulators and targeted agents for treating neuroblastoma.
Jin Z; Lu Y; Wu Y; Che J; Dong X
Eur J Med Chem; 2020 Dec; 207():112818. PubMed ID: 32937281
[TBL] [Abstract][Full Text] [Related]
19. Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer.
Awada G; Gombos A; Aftimos P; Awada A
Expert Opin Emerg Drugs; 2016; 21(1):91-101. PubMed ID: 26817602
[TBL] [Abstract][Full Text] [Related]
20. Current management of neuroblastoma and future direction.
Pastor ER; Mousa SA
Crit Rev Oncol Hematol; 2019 Jun; 138():38-43. PubMed ID: 31092383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
